JNJ (Johnson & Johnson) Stock Financials & Earnings

Company Info & Key Metrics

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health ...

CEOJoaquin Duato

Country🇺🇸 United States

ExchangeNYSE

IPOJan 2, 1943

www.jnj.com

Revenue$24.6B

YoY Growth+9.1%

QoQ Growth+2.4%

Net Income$5.1B

EPS$2.10

Free Cash Flow$5.5B

Gross Margin86.4%

Op. Margin21.9%

Net Margin20.8%

FCF Margin22.3%

Rev Multiple (TTM)6.2x

P/E Ratio (TTM)21.8x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$20.9B	$14.2B	$6.2B
Q2 23	$21.5B	$15.1B	$6.4B
Q3 23	$21.4B	$14.7B	$6.2B
Q4 23	$21.4B	$14.6B	$4.6B
Q1 24	$21.4B	$14.9B	$6.3B
Q2 24	$22.4B	$15.6B	$6.7B
Q3 24	$22.5B	$15.5B	$5.3B
Q4 24	$22.5B	$15.4B	$3.8B
Q1 25	$21.9B	$14.5B	$6.3B
Q2 25	$23.7B	$16.1B	$6.8B
Q3 25	$24.0B	$16.7B	$7.1B
Q4 25	$24.6B	$21.2B	$5.4B

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	6.6x	45.9x
Q2 23	6.8x	44.8x
Q3 23	6.7x	16.9x
Q4 23	6.9x	16.6x
Q1 24	6.8x	15.2x
Q2 24	6.8x	15.4x
Q3 24	6.7x	39.8x
Q4 24	6.6x	41.6x
Q1 25	6.5x	26.8x
Q2 25	6.5x	25.8x
Q3 25	6.3x	23.3x
Q4 25	6.2x	21.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$3.3B	$2.4B
Q2 23	$4.2B	$3.1B
Q3 23	$7.5B	$6.5B
Q4 23	$7.9B	$6.3B
Q1 24	$3.7B	$2.9B
Q2 24	$5.6B	$4.7B
Q3 24	$8.0B	$5.7B
Q4 24	$7.0B	$4.8B
Q1 25	$4.2B	$3.4B
Q2 25	$3.9B	$2.5B
Q3 25	$9.2B	$8.4B
Q4 25	$7.3B	$5.5B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$863M
Q2 23	$1.1B
Q3 23	$967M
Q4 23	$1.6B
Q1 24	$807M
Q2 24	$976M
Q3 24	$2.3B
Q4 24	$2.1B
Q1 25	$809M
Q2 25	$1.4B
Q3 25	$788M
Q4 25	$1.8B

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-10.8%	-15.4%
Q2 23	-10.4%	-13.6%
Q3 23	+6.8%	+5.7%
Q4 23	-9.7%	-15.2%
Q1 24	+2.3%	+3.2%
Q2 24	+4.3%	+4.1%
Q3 24	+5.2%	+13.5%
Q4 24	+5.3%	+11.3%
Q1 25	+2.4%	+3.2%
Q2 25	+5.8%	+7.2%
Q3 25	+6.8%	-1.7%
Q4 25	+9.1%	+2.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$306M	1.5%
Q2 23	$382M	1.8%
Q3 23	$296M	1.4%
Q4 23	$178M	0.8%
Q1 24	$302M	1.4%
Q2 24	$341M	1.5%
Q3 24	$295M	1.3%
Q4 24	$238M	1.1%
Q1 25	$288M	1.3%
Q2 25	$410M	1.7%
Q3 25	$347M	1.4%
Q4 25	$309M	1.3%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$3.5B	$4.5B
Q2 23	$3.7B	$5.0B
Q3 23	$3.4B	$5.1B
Q4 23	$4.5B	$5.5B
Q1 24	$3.5B	$5.1B
Q2 24	$3.4B	$5.5B
Q3 24	$5.0B	$5.3B
Q4 24	$5.3B	$6.3B
Q1 25	$3.2B	$5.0B
Q2 25	$3.5B	$5.8B
Q3 25	$3.7B	$5.9B
Q4 25	$4.3B	$7.0B

Revenue Segments

Quarter	Innovative Medicine	Med Tech
Q3 23	$13.9B	$7.5B
Q4 23	$13.7B	$7.7B
Q1 24	$13.6B	$7.8B
Q2 24	$14.5B	$8.0B
Q3 24	$14.6B	$7.9B
Q4 24	$14.3B	$8.2B
Q1 25	$13.9B	$8.0B
Q2 25	$15.2B	$8.5B
Q3 25	$15.6B	$8.4B
Q4 25	$15.8B	$8.8B

Revenue by Geography

Quarter	Asia-Pacific, Africa	Europe	United States	Western Hemisphere, excluding U.S.
Q3 23	$3.5B	$4.7B	$12.0B	$1.2B
Q1 24	$3.4B	$5.2B	$11.6B	$1.2B
Q2 24	$3.5B	$5.2B	$12.6B	$1.2B
Q3 24	$3.5B	$4.9B	$12.9B	$1.2B
Q4 24	$3.3B	$4.9B	$13.2B	$1.1B
Q1 25	$3.3B	$5.1B	$12.3B	$1.2B
Q2 25	$3.6B	$5.4B	$13.5B	$1.2B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$19.2B	$5.4B	$24.6B
Q2 23	$21.2B	$7.3B	$28.5B
Q3 23	$19.7B	$3.8B	$23.5B
Q4 23	$21.9B	$1.1B	$22.9B
Q1 24	$25.5B	$745M	$26.2B
Q2 24	$24.9B	$597M	$25.5B
Q3 24	$20.0B	$317M	$20.3B
Q4 24	$24.1B	$417M	$24.5B
Q1 25	$38.5B	$307M	$38.8B
Q2 25	$18.6B	$303M	$18.9B
Q3 25	$18.2B	$331M	$18.6B
Q4 25	$19.7B	$393M	$20.1B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	2.61B	-2.2%
Q2 23	2.63B	+0.8%
Q3 23	2.55B	-2.9%
Q4 23	2.43B	-4.7%
Q1 24	2.43B	-0.0%
Q2 24	2.42B	-0.3%
Q3 24	2.43B	+0.2%
Q4 24	2.43B	-0.0%
Q1 25	2.42B	-0.1%
Q2 25	2.42B	-0.2%
Q3 25	2.43B	+0.4%
Q4 25	2.44B	+0.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$588K	127K
FY 15	$554K	127K
FY 16	$566K	127K
FY 17	$571K	134K
FY 18	$604K	135K
FY 19	$621K	132K
FY 20	$614K	135K
FY 21	$556K	142K
FY 22	$524K	153K
FY 23	$646K	132K
FY 24	$643K	138K
FY 25	$682K	138K